Accéder au contenu
Merck

Synthesis and in vitro evaluation of 1,2,4-triazolo[1,5-a][1,3,5]triazine derivatives as thymidine phosphorylase inhibitors.

Chemical biology & drug design (2013-06-14)
Hriday Bera, Anton V Dolzhenko, Lingyi Sun, Sayan Dutta Gupta, Wai-Keung Chui
RÉSUMÉ

In our lead finding program, a series of 1,2,4-triazolo[1,5-a][1,3,5]triazine derivatives were synthesized, and their in vitro thymidine phosphorylase inhibitory potential was explored. Among the different derivatives, compounds having keto group (C = O) at C7 and thioketo group (C = S) at C5 positions showed varying degrees of TP inhibitory activity comparable with positive control, 7-deazaxanthine (7-DX, 2) (IC50 value = 42.63 μm). Enzyme inhibition kinetics study suggested that compound IVn behaved as a mixed-type inhibitor of the enzyme with respect to thymidine (dThd) as a variable substrate. Compound IVn was also found to inhibit PMA-induced MMP-9 expression in MDA-MB-231 cells at sublethal concentrations. Computational docking study was performed to illustrate the enzyme inhibition kinetics and to explore the ligand-enzyme interactions.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Thymidine Phosphorylase, recombinant from Escherichia coli, recombinant, expressed in E. coli, buffered aqueous solution, ≥500 units/mL
Sigma-Aldrich
Thymidine Phosphorylase, recombinant from Escherichia coli, recombinant, expressed in E. coli, Suitable for manufacturing of diagnostic kits and reagents, buffered aqueous solution, ≥500 units/mL
Sigma-Aldrich
Thymidine Phosphorylase, recombinant from Escherichia coli, recombinant, expressed in E. coli, buffered aqueous solution, ≥900 units/mL, 0.2 μm filtered